DoD Peer Reviewed Cancer, Impact Award | HT9425 23 PRCRP IPA

Opportunity Information: Apply for HT9425 23 PRCRP IPA

The DoD Peer Reviewed Cancer Research Program (PRCRP) Impact Award (FY23) is a Department of Defense funding opportunity designed to push cancer research toward results that can matter to patients in the near term. It specifically targets hypothesis-driven projects that are already mature and well-supported by prior work, rather than early exploratory concepts. The central idea is to fund research that tackles a critical scientific or clinical cancer problem and can credibly produce a major, tangible impact aligned with at least one of the FY23 PRCRP Topic Areas. Reviewers are directed to look closely at whether the proposed work is clinically applicable, whether it builds logically and continuously from a solid foundation of prior research, and whether it leverages real-world clinical resources such as patient samples, ongoing or planned clinical studies, and clinical trials.

A defining feature of this mechanism is its emphasis on impact that goes beyond incremental progress. The project can represent a next step in an existing line of research, but it must be a significant step that meaningfully advances the field toward improved patient outcomes. Applications need to clearly explain how the work will transform cancer research or care within a relatively short time horizon, not just add another piece of knowledge. For that reason, the Impact Award is positioned for translational and clinical research, and it explicitly allows clinical trials as part of the proposed effort. In contrast, it is not meant for basic research. Investigators who are still generating preliminary findings, proposing foundational biology work, or pursuing high-risk/high-reward concepts without a mature evidence base are steered toward the PRCRP Idea Award mechanism instead.

Strong preliminary data is not optional for this award. Applicants must include data that demonstrates feasibility and supports the hypothesis, with an expectation that unpublished preliminary results come from the Principal Investigator or members of the research team. This requirement reinforces that the Impact Award is intended to capitalize on existing momentum and prior discoveries, using them as a springboard to produce outcomes that can realistically be translated into treatment strategies, prevention approaches, or other clinically meaningful applications.

Another major requirement is rigor in study design and evaluation. Proposals are expected to include a clear statistical plan and a data analysis plan, reflecting the program’s focus on reliability, robustness, and interpretability. Because the program emphasizes patient relevance, the evaluation approach should be framed in terms of how results will translate to patient outcomes, clinical decision-making, or advancement toward implementation. In other words, it is not enough to collect data; the application needs to show a credible path for how that data will be analyzed and how the resulting evidence could move the needle in clinical or translational settings.

Administratively, this opportunity is offered by the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). The funding opportunity number is HT9425-23-PRCRP-IPA, and awards may be made as grants and/or cooperative agreements under CFDA 12.420 (science and technology and other research and development). Eligibility is described as unrestricted, meaning a wide range of entity types may apply as long as they meet any conditions stated in the full announcement. The posting indicates an expected 11 awards. The original closing date listed for this FY23 opportunity was September 12, 2023.

Overall, the FY23 PRCRP Impact Award is best understood as a mechanism for established teams with convincing preliminary evidence who are ready to translate an advanced research line into near-term clinical value. The most competitive applications will read like a clear, disciplined plan to convert prior discoveries into outcomes that could plausibly influence patient care, prevention, or clinical research practice soon, using strong design, appropriate statistics, and meaningful clinical linkages such as samples, cohorts, or trials.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Cancer, Impact Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 04, 2023.
• Applicants must submit their applications by Sep 12, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 11 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 PRCRP IPA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: